scholarly journals Videocapillaroscopy, Insulin-Induced Skin Lipohypertrophy, and Bruising: A Preliminary Approach

2021 ◽  
pp. 1-4
Author(s):  
Teresa Della Corte ◽  
◽  
Gentile S ◽  
Guarino G ◽  
Cuomo G ◽  
...  
Keyword(s):  
Metabolic Control ◽  
Daily Injection ◽  
Skin Changes ◽  
Multiple Daily Injection ◽  
Poor Metabolic Control ◽  
Type 2 Dm ◽  
Injection Regimen

Background: Lipohypertrophy (LH) is a frequent cutaneous complication in people with insulin-treated type-2 DM (IT-T2DM). Its pathogenesis is not fully known, however. Retinal and kidney microangiopathy (MIA) is also frequent in such patients, especially in case of poor metabolic control. Aim: To assess whether specific nailfold video-capillaroscopy (NVC) patterns could be identified in MIA-affected IT-T2DM patients, thus eventually helping explain LH pathogenesis. Methods: 50 IT-T2DM patients with LH and 50 without LH undergoing NVC were enrolled. All followed a multiple daily injection regimen and had established retinal and renal microangiopathic complications. Results: While confirming expected MIA-related skin changes in both groups, our data failed to detect any specific NVC pattern in LH-affected patients yet showed the most severe NVC changes to be significantly associated with HbA1c values over 9%. Conclusion: Severe NVC-assessed MIA lesions reflect longstanding poor metabolic control in IT-T2DM rather than contributing to LH pathogenesis.

scholarly journals Insulin pump therapy in children with diabetes mellitus: practice of Krasnoyarsk Krai

2012 ◽  
Vol 15 (4) ◽  
pp. 46-60
Author(s):  
Tatiana Evgen'evna Taranushenko ◽  
Viktoriya Nikolaevna Panfilova ◽  
Oksana Alekseevna Terent'eva ◽  
Nadezhda Dmitrievna Koreshkova ◽  
Maria Nikolaevna Petrova
Keyword(s):  
Diabetes Mellitus ◽  
Insulin Pump ◽  
Laboratory Data ◽  
Severe Hypoglycemia ◽  
Insulin Pump Therapy ◽  
Daily Injection ◽  
Krasnoyarsk Krai ◽  
Pump Therapy ◽  
Multiple Daily Injection ◽  
Injection Regimen

Aim. To summarize practical experience of insulin pump therapy (IPT) in child population of Krasnoyarsk and to assess its efficacy for treatment of type 1 diabetes mellitus (T1DM) in paediatrics. Materials and Methods. We performed a comparative analysis of clinical and laboratory data from 48 children with T1DM prior to and after 6-12 months of IPT. Results. IPT yielded fourfold decrease in complaints of hyperglycemia and labile glycemia without concurrent increase in reports of severe hypoglycemia.  We observed a trend for lowering of mean HbA1c levels, where 65% of patients showed positive dynamics in comparison with the period of multiple daily injection regimen. Interestingly, after 6-12 months of IPT, insulin requirement dropped in most patients. Conclusion. Our data support clinical efficiency and safety of IPT, as well as superiority of this treatment over multiple daily injection regimen. We conclude that IPT is a treatment of choice for children with T1DM.

scholarly journals Clinical Evaluation of Basal-Bolus Therapy Delivered by the V-Go® Wearable Insulin Delivery Device in Patients with Type 2 Diabetes: A Retrospective Analysis

Pharmacy ◽  
2020 ◽  
Vol 8 (4) ◽  
pp. 215
Author(s):  
Trisha Zeidan ◽  
Carla Nikkel ◽  
Beth Dziengelewski ◽  
Stephanie Wu ◽  
Aleda M. H. Chen
Keyword(s):  
Type 2 Diabetes ◽  
Daily Injection ◽  
Total Daily Dose ◽  
Diabetes Clinic ◽  
Multiple Daily Injection ◽  
Daily Dose ◽  
Study Completion ◽  
Glycemic Targets ◽  
Basal Bolus

Insulin therapy is frequently required to achieve glycemic targets (A1c) in type 2 diabetes (T2D); however, clinicians and patients face barriers with the complexities of multiple daily injection regimens. Patch-like wearable insulin devices, such as V-Go, may simplify and optimize this complexity. This study evaluated the change in A1C and insulin total daily dose (TDD) in a suboptimally-controlled (not achieving A1C targets) T2D population after switching to V-Go. A retrospective chart analysis at a diabetes clinic was performed to evaluate change in A1c measurements from baseline (V-Go initiation) to end of study observation. Of the 139 patients enrolled, A1C significantly decreased from baseline (−1.5 ± 1.79%; p < 0.001). Patients prescribed insulin at baseline (n = 122) used significantly less insulin TDD (−8 u/day; p = 0.006). The percentage of patients meeting the target of A1C < 8% increased from 14% at baseline to 48% at study completion (p = 0.008). Patients prescribed a basal-bolus regimen prior to V-Go achieved an A1C reduction of 1.5 ± 2.0% (p < 0.0001) and experienced the greatest reduction in TDD (−24 u/day; p < 0.0001). Thus, patients switching to V-Go from a variety of therapies at baseline experienced reductions in A1C while using less insulin, with a reduction in clinically relevant hypoglycemia, indicating the potential benefit of V-Go in optimizing and simplifying T2D care.

scholarly journals Cardiovascular Endurance and Heart Rate Variability in Adolescents With Type 1 or Type 2 Diabetes

2005 ◽  
Vol 7 (1) ◽  
pp. 16-29 ◽  
Author(s):  
Melissa Spezia Faulkner ◽  
Laurie Quinn ◽  
James H. Rimmer ◽  
Barry H. Rich
Keyword(s):  
Physical Activity ◽  
Type 2 Diabetes ◽  
Heart Rate ◽  
Heart Rate Variability ◽  
Metabolic Control ◽  
Cardiovascular Endurance ◽  
Type 2 Dm ◽  
Type 1 Dm

Background. Incidence rates of both type 1 and type 2 diabetes mellitus (DM) are increasing in youth and may eventually contribute to premature heart disease in early adulthood. This investigation explored the influence of type of diabetes, gender, body mass index (BMI), metabolic control (HbA1c), exercise beliefs and physical activity on cardiovascular endurance (CE), and heart rate variability (HRV). Differences in exercise beliefs, physical activity, HRV, and CE in youth with type 1 versus type 2 DM were determined. Methods. Adolescents with type 1 DM (n = 105) or with type 2DM (n = 27) completed the Exercise Belief Instrument and the Physical Activity Recall. Twenty-four HRV measures were obtained via Holter monitoring and analyzed using SpaceLabs Vision Premier™ software system. The McMaster cycle test was used to measure CE (V02peak). Results. Regardless of the type of DM, females and those with higher BMI, poorer metabolic control, and lower amounts of physical activity tended to have lower levels of CE. Exercise beliefs consistently predicted both frequency and time domain HRV measures. Measures of exercise beliefs, self-reported physical activity, CE (V02peak), and HRV were significantly lower in adolescents with type 2 DM in comparison to those with type 1 DM. Conclusions and Recommendations. Early findings of poor physical fitness, lower HRV, fewer positive beliefs about exercise, and less active lifestyles highlight the importance of developing culturally sensitive interventions for assisting youth to make lifelong changes in their physical activity routines. Females, those with poorer metabolic control, and minority youth with type 2 DM may be particularly vulnerable to later cardiovascular disease.

Systemic prostaglandin E1 infusion and hepatic aminonitrogen to urea nitrogen conversion in patients with type 2 diabetes in poor metabolic control

Metabolism ◽  
2001 ◽  
Vol 50 (2) ◽  
pp. 253-258 ◽  
Author(s):  
Giulio Marchesini ◽  
Valeria Zaccheroni ◽  
Mara Brizi ◽  
Stefania Natale ◽  
Gabriele Forlani ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Metabolic Control ◽  
Prostaglandin E1 ◽  
Urea Nitrogen ◽  
Poor Metabolic Control ◽  
Nitrogen Conversion

scholarly journals Changed Diabetic Treatment from Multiple Daily Injection (MDI), Dulaglutide to Xultophy

2021 ◽  
Vol 4 (1) ◽  
pp. 77-83
Author(s):  
Bando H ◽  
Kato Y ◽  
Kato Y ◽  
Matsuzaki S ◽  
Waka S ◽  
...  
Keyword(s):  
Renal Stone ◽  
Synergistic Effects ◽  
Glucose Variability ◽  
Diabetic Control ◽  
Daily Injection ◽  
Left Adrenal Gland ◽  
Multiple Daily Injection ◽  
Medical Histories ◽  
Diabetic Treatment

The patient is a 56-year old (yo) female with type 2 diabetes mellitus (T2DM). Medical histories include persisting T2DM from 35yo, renal stone at 43yo, hypertension from 45yo, photocoagulation for retinopathy on 54yo. An incidentaloma was found in the left adrenal gland, where endocrinological exams were negative for functional tumor. Her diabetic control situation became worse with HbA1c > 10%, then the treatment has been changed from multiple daily injection (MDI), Dulaglutide to Xultophy which is combined agents of degludec and liraglutide (IDegLira). It was provided 10-18 doses daily, and then glucose variability profile was improved satisfactory, suggesting the dual synergistic effects.

Sign in / Sign up

Export Citation Format

Share Document